WUHAN and SAN DIEGO, April 6, 2023 – Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the company’s leading candidate NR082 has initiated multiple clinical research centers in the U.S. and started patient screening.

Investigational NR082(rAAV2-ND4) is an in vivo gene therapy in development for the treatment of Leber hereditary optic neuropathy (LHON) associated with ND4 mutations. The approved clinical trial is a single-arm, multicenter, Phase I/II clinical study investigating the safety, tolerability, and efficacy of NR082 in LHON patients with ND4 mutations. After completing patient enrollment for Phase III clinical trial of NR082 in China, the initiation of clinical trial in the U.S. marks a significant milestone for Neurophth in pursuit of bringing innovative drug overseas.